Analgesic efficacy of adjuvant nefopam on patient controlled analgesia in patients undergoing laparoscopic colorectal cancer surgery
Not Applicable
Recruiting
- Conditions
- Neoplasms
- Registration Number
- KCT0005037
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
patients with colorectal cancer who underwent laparoscopic colorectal surgery from January 2015 to April 2020
Exclusion Criteria
emergent surgery, metastatic colorectal lesions, conversion to open surgery, the need for intensive care unit management after surgery, inability to express pain severity, patients who were taken non-opioid analgesics during anesthesia, and patients with nefopam contraindications
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method postoperative pain score
- Secondary Outcome Measures
Name Time Method postoperative analgesic dose
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the analgesic mechanism of nefopam in laparoscopic colorectal cancer surgery?
How does nefopam compare to standard-of-care analgesics in postoperative pain management for colorectal cancer patients?
Are there specific biomarkers that predict response to nefopam as an adjuvant analgesic in laparoscopic colorectal cancer surgery?
What are the potential adverse events associated with nefopam use in patient-controlled analgesia for colorectal cancer surgery?
What combination analgesic strategies are being explored alongside nefopam for laparoscopic colorectal cancer surgery?